Celularity Inc


Prices are adjusted according to historical splits.

Celularity Inc Stock Price


Today's Low:
Today's High:
Open Price:
52W Low:
52W High:
Prev. Close:

Company Statistics

Market Cap.:
$90.60 million
Book Value:
Revenue TTM:
$18.70 million
Operating Margin TTM:
Gross Profit TTM:
$11.68 million
Profit Margin:
Return on Assets TTM:
Return on Equity TTM:

Company Profile

Celularity Inc had its IPO on 2019-08-08 under the ticker symbol CELU.

The company operates in the Healthcare sector and Biotechnology industry. Celularity Inc has a staff strength of 225 employees.

Stock update

Shares of Celularity Inc opened at $0.63 at the start of the last trading session i.e. 2023-03-25.

The stocks traded within a range of $0.57 - $0.64, and closed at $0.59.

This is a -1.67% slip from the previous day's closing price.

A total volume of 163,800 shares were traded at the close of the day’s session.

In the last one week, shares of Celularity Inc have slipped by -4.23%.

Celularity Inc's Key Ratios

Celularity Inc has a market cap of $90.60 million, indicating a price to book ratio of 1.3244 and a price to sales ratio of 11.6308.

In the last 12-months Celularity Inc’s revenue was $18.70 million with a gross profit of $11.68 million and an EBITDA of $-132655000. The EBITDA ratio measures Celularity Inc's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Celularity Inc’s operating margin was -760.66% while its return on assets stood at -20.08% with a return of equity of -10.97%.

In Q3, Celularity Inc’s quarterly earnings growth was a negative -92.5% while revenue growth was a negative 61.1%.

Celularity Inc’s PE and PEG Ratio

Forward PE
Trailing PE

Its diluted EPS in the last 12-months stands at $0.45 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Celularity Inc’s profitability.

Celularity Inc stock is trading at a EV to sales ratio of 12.9421 and a EV to EBITDA ratio of -62.0623. Its price to sales ratio in the trailing 12-months stood at 11.6308.

Celularity Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets
$437.12 million
Total Liabilities
$69.22 million
Operating Cash Flow
Capital Expenditure
$1.56 million
Dividend Payout Ratio

Celularity Inc ended 2023 with $437.12 million in total assets and $0 in total liabilities. Its intangible assets were valued at $437.12 million while shareholder equity stood at $164.24 million.

Celularity Inc ended 2023 with $10000.00 in deferred long-term liabilities, $69.22 million in other current liabilities, 14000.00 in common stock, $-669930000.00 in retained earnings and $123.30 million in goodwill. Its cash balance stood at $42.65 million and cash and short-term investments were $42.65 million. The company’s total short-term debt was $39,255,000 while long-term debt stood at $0.

Celularity Inc’s total current assets stands at $63.10 million while long-term investments were $0 and short-term investments were $0. Its net receivables were $4.45 million compared to accounts payable of $9.22 million and inventory worth $5.24 million.

In 2023, Celularity Inc's operating cash flow was $-1563000.00 while its capital expenditure stood at $1.56 million.

Comparatively, Celularity Inc paid $0 in dividends in 2023.

Other key metrics

Current Trading Price
52-Week High
52-Week Low
Analyst Target Price

Celularity Inc stock is currently trading at $0.59 per share. It touched a 52-week high of $13.186 and a 52-week low of $13.186. Analysts tracking the stock have a 12-month average target price of $8.1.

Its 50-day moving average was $0.8 and 200-day moving average was $2.11 The short ratio stood at 5.45 indicating a short percent outstanding of 0%.

Around 6147.3% of the company’s stock are held by insiders while 2281.9% are held by institutions.

Frequently Asked Questions About Celularity Inc

The stock symbol (also called stock or share ticker) of Celularity Inc is CELU

The IPO of Celularity Inc took place on 2019-08-08

Similar Industry Stocks (Biotechnology)

Last Price
Ryvyl Inc (RVYL)

Most Active

Last Price

Top Gainers

Last Price

Top Losers

Last Price
Imara Inc (IMRA)


Celularity Inc., a clinical-stage biotechnology company, develops off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer, immune, and infectious diseases. It operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. The company’s lead therapeutic programs include CYCART-19, a placental-derived CAR-T therapy, which is in Phase I clinical trial for the treatment of B-cell malignancies; CYNK-001, placental-derived unmodified natural killer (NK) cell that is in Phase I clinical trial to treat acute myeloid leukemia, as well as in Phase I/IIa clinical trial for the treatment of glioblastoma multiforme and COVID-19; CYNK-101, an allogeneic genetically modified NK cell, which is in Phase I clinical trial to treat HER2+ gastric and gastroesophageal cancers; APPL-001, a placenta-derived mesenchymal-like adherent stromal cell that is in a pre-clinical stage for the treatment of Crohn’s disease; and PDA-002, a placenta-derived mesenchymal-like adherent stromal cell, which is in pre-clinical stage for the treatment of facioscapulohumeral muscular dystrophy. It also sells and licenses products that are used in surgical and wound care markets, such as Biovance and Interfyl; collects stem cells from umbilical cords and placentas; and provides cells storage under the LifebankUSA brand. The company was incorporated in 2016 and is headquartered in Florham Park, New Jersey.


170 Park Avenue, Florham Park, NJ, United States, 07932